Brief: EMA's CHMP Re-Examines Rejection Of Kisunla For Early Alzheimer’S Treatment

Madrigal Pharmaceuticals

20/06/2025 11:17

June 20 (Reuters) - EMA's CHMP:

POSITIVE OPINION WAS ADOPTED FOR OGSIVEO, FOR THE TREATMENT OF ADULTS WITH PROGRESSING DESMOID TUMOURS

NINTEDANIB VIATRIS GOT POSITIVE OPINION  FOR TREATMENT OF IDIOPATHIC PULMONARY FIBROSIS, CHRONIC FIBROSING INTERSTITIAL LUNG DISEASES

RECOMMENDED GRANTING CONDITIONAL MARKETING AUTHORISATION FOR REZDIFFRA, FOR TREATMENT OF ADULTS WITH NONCIRRHOTIC MASH

RECOMMENDED GRANTING MARKETING AUTHORISATION FOR AUSTEDO FOR TREATMENT OF ADULTS WITH MODERATE-TO-SEVERE TARDIVE DYSKINESIA

POSITIVE OPINION FOR TENOFOVIR ALAFENAMIDE  FOR TREATMENT OF ADULTS AND ADOLESCENTS INFECTED WITH HIV-1

STARTED RE-EXAMINATION OF ITS MARCH 2025 RECOMMENDATION NOT TO GRANT A MARKETING AUTHORISATION FOR KISUNLA ON JUNE 2

Source text: [ID:]

Further company coverage: SWTX.O

 ((Reuters.Briefs@thomsonreuters.com;))